Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.50 |
| ▸ | AXL | P30530 | 11/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23043880 | 1.00 | MET (0.50) | METAXLRAB9AMEN1KMT2A | |
| SCHEMBL23044069 | 0.99 | RAB9A (0.49) | METAXLRAB9AMEN1KMT2A | |
| SCHEMBL29746523 | 0.99 | RAB9A (0.49) | METAXLRAB9AMEN1KMT2A | |
| SCHEMBL29746657 | 0.97 | MET (0.47) | METAXLRAB9AMEN1KMT2A | |
| SCHEMBL23043898 | 0.97 | MET (0.47) | METAXLRAB9AMEN1KMT2A | |
| SCHEMBL23043945 | 0.95 | MET (0.47) | METAXLRAB9AMEN1KMT2A | |
| SCHEMBL29746589 | 0.95 | MET (0.47) | METAXLRAB9AMEN1KMT2A | |
| SCHEMBL23043903 | 0.83 | FLT3 (0.50) | METAXLFLT3MAP4K4CYP3A4 | |
| SCHEMBL23043972 | 0.81 | EIF2AK3 (0.52) | METAXLFLT3MAP4K4SMN1; SMN2 | |
| SCHEMBL23044049 | 0.81 | EIF2AK3 (0.51) | METAXLMEN1KMT2AFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | HIBERCELL, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-4021908-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356186-A1 | PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | EEF2K, ATF4, MAPKAPK2 | MET 839/4885AXL 3904/4885RAB9A 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.